The company develops synthetic phages targeting specific bacteria using a virtual phage database derived from human genome analysis, eliminating the need to isolate phages from natural sources. This approach provides the medical industry with novel drug delivery methods for the treatment and prevention of bacterial infections.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods of phage discovery for antibacterial therapies rely on isolating phages from environmental samples, a process that is time-consuming, resource-intensive, and often yields phages with limited therapeutic potential. This dependence on natural sources restricts the diversity of phages available for development and hinders the rapid response to emerging antibiotic-resistant bacteria.
Solution
The company is developing synthetic phages by leveraging a virtual phage database derived from human genome analysis, eliminating the need to isolate phages from natural sources. This computational approach enables the design of novel phages with targeted antibacterial activity and improved drug delivery capabilities. By creating phages de novo, the company can rapidly generate customized solutions to combat specific bacterial infections and address the growing threat of antimicrobial resistance. The synthetic phages are designed for enhanced stability, reduced immunogenicity, and precise targeting of pathogenic bacteria, offering a more effective and safer alternative to traditional antibiotics.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers seeking novel antibacterial therapies and drug delivery methods to combat bacterial infections and address antimicrobial resistance.
Features
- Virtual phage database derived from human genome analysis for in silico phage design
- Computational modeling to predict phage-bacteria interactions and optimize targeting specificity
- De novo synthesis of phages with customized antibacterial activity
- Enhanced phage stability and reduced immunogenicity for improved therapeutic efficacy
- Targeted drug delivery to bacterial cells using synthetic phages as vectors